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ABSTRACT
TarFisDock is a web-based tool for automating the
procedure of searching for small molecule–protein
interactions over a large repertoire of protein struc-
tures. It offers PDTD (potential drug target database),
a target database containing 698 protein structures
covering 15 therapeutic areas and a reverse ligand–
protein docking program. In contrast to conven-
tionalligand–proteindocking,reverseligand–protein
docking aims to seek potential protein targets by
screening an appropriate protein database. The
input file of this web server is the small molecule
to be tested, in standard mol2 format; TarFisDock
then searches for possible binding proteins for the
given small molecule by use of a docking approach.
The ligand–protein interaction energy terms of the
program DOCK are adopted for ranking the proteins.
To test the reliability of the TarFisDock server, we
searched the PDTD for putative binding proteins
for vitamin E and 4H-tamoxifen. The top 2 and 10%
candidates of vitamin E binding proteins identified
by TarFisDock respectively cover 30 and 50% of
reported targets verified or implicated by experi-
ments; and 30 and 50% of experimentally confirmed
targets for 4H-tamoxifen appear amongst the top 2
and 5% of the TarFisDock predicted candidates,
respectively. Therefore, TarFisDock may be a useful
tool for target identification, mechanism study of old
drugs and probes discovered from natural products.
TarFisDock and PDTD are available at http://www.
dddc.ac.cn/tarfisdock/.
INTRODUCTION
Recent advances in the development of tools for docking
small molecules to proteins, i.e. virtual screening, has demon-
strated the efﬁciency of this approach for the discovery of
potential lead compounds for drug development in the post-
genomic era (1–3). Numerous docking programs (4–10) have
been used to seek ligands which recognize the 3D structure of
a given target obtained by X-ray crystallography, NMR spec-
troscopy or even by homology modeling [for a review com-
paring and evaluating docking tools see ref. (11)]. However,
identiﬁcation and validation of druggable targets from
amongst thousands of candidate macromolecules is still a
challenging task (12,13). A proteomic approach for identiﬁ-
cation of binding proteins for a given small molecule involves
comparison of the protein expression proﬁles for a given cell
or tissue inthe presence or absence of the givenmolecule.This
method has not proved very successful in target discovery
because it is laborious and time-consuming (14). Thus an
efﬁcient computational method for identifying the targets of
a small molecule which had been demonstrated experiment-
ally to have an important biological activity would provide a
tool of great potential value. An alternative approach that
has shown promise in recent years is to use computational
methods to ﬁnd putative binding proteins for a given
compound from either genomic or protein databases, and
subsequently useexperimental procedures tovalidatethe com-
putational result (15–18). One such computational approach,
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target, is to dock a compound with a known biological activity
into the binding sites of all the 3D structures in a given protein
database. Protein ‘hits’ so identiﬁed can then serve as potential
candidates for experimental validation. Accordingly, this
approach is referred to as reverse docking.
Herein, we present a web-based tool Target Fishing
Dock (TarFisDock) for seeking potential binding proteins
for a given ligand. It makes use of a ligand–protein reverse
docking strategy to search out all possible binding proteins for
a small molecule from the potential drug target database
(PDTD). The small molecule might be a biologically active
compound detected in a cell- or animal-based bioassay screen,
a natural product or an existing drug whose molecular target(s)
is (are) unknown. Thus, TarFisDock may serve as a valuable
tool for identifying targets for a novel synthetic compound or
for a newly isolated natural product, for a compound with
known biological activity, or for an existing drug whose
mechanism of action is unknown.
METHODS
Construction of the potential drug target database
TarFisDock requires a sufﬁcient number of known protein
structures covering a diverse range of drug targets. The target
proteins collected in PDTD were selected from the literature
(19–22), and from several online databases, such as DrugBank
(http://redpoll.pharmacy.ualberta.ca/drugbank/) (23), and
TTD (http://bidd.nus.edu.sg/group/cjttd/) (24). Only proteins
with known 3D structures were deposited in PDTD, the
Protein Data Bank (PDB) (25) being the major source of
their coordinates. PDTD currently consists of 698 entries
covering 371 drug targets. These drug targets may be categor-
ized into 15 types, according to their therapeutic areas (20,22),
as shown in Table 1. Because TarFisDock does not take into
account protein ﬂexibility, PDTD includes redundant entries
for proteins known to be ﬂexible. Thus, for example, there are
seven entries for HIV-1 (Figure 1).
Water molecules and complexed ligands were removed
from the protein structures, after which hydrogen atoms
were added, and KOLLMAN charges (26), with the protona-
tion state of the individual residues being taken into account
during charge assignment. A mo12 ﬁle (Mol2 ﬁle (.mol2)
developed by SYBYL, Tripos Inc., St Louis, USA (http://
www.tripos.com/) is a complete, portable representation of
a SYBYL molecule. It is an ASCII ﬁle which contains all
the information needed to reconstruct a SYBYL molecule.)
was then constructed for each protein. The active site of each
protein was deﬁned as all residues within 6.5 s of the ligand
bound, and a sphere ﬁle for the active site was generated using
the SPHGEN program (27). The PDB, mol2 and sphere ﬁles
for each protein were stored in PDTD.
Reverse docking procedure using TarFisDock
TarFisDock consists of two parts, a front-end web interface
written in both PHP and HTML, with MySQL as database
system, and a back-end tool for reverse docking. TarFisDock
was developed on the basis of the widely used docking
program, DOCK (version 4.0) (5,27). The reverse docking
procedure is as follows: (i) TarFisDock either generates
a protein target list according to the user’s preference (see
INPUT) or selects all the protein entries in the PDTD if
the user intends to ﬁnd a new target or targets for an active
compound; (ii) TarFisDock docks a given small molecule into
the possible binding sites of proteins in the target list, and the
interaction energies between the small molecule and the
proteins are calculated and recorded; (iii) TarFisDock ana-
lyzes the reverse docking result. In general, TarFisDock
may output the top 2, 5 or 10% of the ranking list, from
which the user may select protein candidates for further
biological study. So far, TarFisDock has taken into account
the ﬂexibility of the small molecules, but has not yet taken into
account protein ﬂexibility. Putative binding proteins are selec-
ted by ranking the values of the interaction energy (Einter),
which is composed of van der Waals and electrostatic inter-
action terms (Equation 1),
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where each term is a double sum over ligand atoms i and
receptor atoms j; rij is the distance between atom i in the ligand
and atom j in the putative receptor protein; Aij and Bij are van
der Waals repulsion and attraction parameters, respectively; a
andbarethevanderWaals repulsionandattractionexponents,
respectively; qi and qj are point charges on atoms i and j; D is
dielectric function; and 332.0 is the factor that converts the
electrostatic energy into kcal/mol. The Amber force ﬁeld (26)
was used for the energy calculation.
INPUT, OUTPUT AND OPTIONS
The input ﬁle consists of only the test small molecule in
standard mol2 format. The 2D structure of a small molecule
can be either sketched using ISIS/Draw (ISIS/Draw, MDL
Informations Systems, Inc., San Leandro, CA 945577) or
ChemDraw (ChemDraw, CambridgeSoft Corporation, 875
Massachusetts Avenue, Cambridge, MA 02139, USA) or
taken from such chemical databases as CCD (http://www.
chemnetbase.com/), ACD (http://www.mdli.com/) and
SPECS (http://www.specs.net/). The user can convert the
small molecule from its 2D structures to the 3D structures
by using CORINA (28) (http://www2.chemie.uni-erlangen.
Table 1. Diseases categories of drug targets in PDTD
(1) Synaptic And Neuroeffector Junctional Sites And Central Nervous System
(2) Inflammation
(3) Renal And Cardiovascular Functions
(4) Gastrointestinal Functions
(5) Uterine Motility
(6) Bacterial Infections
(7) Fungal Infections
(8) Viral Infections
(9) Parasitic Infectious Diseases
(10) Immunomodulation
(11) Blood And Blood-Forming Organs
(12) Neoplastic Diseases
(13) Hormones And Hormone Antagonists
(14) The Vitamins
(15) Undefined
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ware. The structures can be minimized by means of molecular
mechanics, and Gasteiger charges (29) should be assigned to
them. Finally, the 3D structure of the small molecule is saved
in a mol2 ﬁle.
Users can register free of charge for using the TarFisDock
server, including access to PDTD. The user must provide his/
her email address and username so as to receive the result.
After registration, the user can login to the server to upload
the mol2 ﬁle of the test molecule, customize a target list
from PDTD, and submit a job (Figure 2). A job identity
number, the ‘job_id’, is assigned to each job by the web server,
and the number is appended to a job queue in the back-end
server. The user may use the job_id to check the status of
his/her job.
The output is delivered in ascending order of energy score
(interaction energy). The archive ﬁle contains a list of the
scores, together with binding models (in mol2 format) of
the small molecule tested within the binding sites of the
candidate targets. The user can also browse the ‘Categories’
dropdown menu of PDTD to obtain detailed information for
the potential target proteins identiﬁed by TarFisDock: the
‘PDB_ID’ ﬁeld contains a hyperlink to the PDB website;
the ‘TARGET NAME’ ﬁeld also contains a hyperlink to
the DrugBank website (Figures 1 and 2), and any information
linking targets to diseases is contained in the ‘RELATED
DISEASE’ ﬁeld taken from TTD.
TEST CASES
To test the reliability of the TarFisDock server, we searched
for the candidate binding proteins for vitamin E and for
4H-tamoxifen. The results and their comparison with the
published experimental data are described below.
Potential binding proteins for vitamin E
Vitamin E is an antioxidant which is widely used as a dietary
supplement (30). It has also been shown to be of therapeutic
value in the treatment of a number of diseases, such as
cardiovascular disease and some forms of cancer, and to
enhance the immune response (31). It is thus likely that vit-
amin E may interact with multiple target proteins. Indeed, 12
targets for vitamin E have already been reported (16) (Sup-
plementary Table S1). Candidate vitamin E-binding proteins
Figure 1. An example of PDTD querying and finding out 22 targets records of ‘[HIV] DISEASE’.
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S2. The top 2% candidates identiﬁed by TarFisDock, ranked
by interaction energies, included 4 out of the 12 targets iden-
tiﬁed experimentally. Three more of these experimentally
identiﬁed targets were in the top 10% of the proteins ranked
by interaction energy. The top 2 and 10% candidates of
vitamin E-binding proteins identiﬁed by TarFisDock cover
30 and 50%, respectively, of reported targets veriﬁed or
implicated by experiments. Other targets, such as glutathione
S-transferase, glutathione synthetase, D-amino acid oxidase,
and guanylyl cyclase (it is not available in PDTD), were not
identiﬁed by TarFisDock (Table 2). The main reason may be
that TarFisDock does not take into account protein ﬂexibility.
It is of interest that many of the top 10% candidate vitamin
E-binding proteins are associated with cancer, cardiovascular
diseases, immune function and dementia (Supplementary
Table S2).
Potential binding proteins for 4H-tamoxifen
4H-tamoxifen is used as an adjuvant therapy in the treatment
of breast cancer (32). Like vitamin E, it is a multiple target
drug. So far, 10 proteins have been identiﬁed as interaction
targets for 4H-tamoxifen or for its metabolite, tamoxifen (16)
(Supplementary Table S1). To test the reliability of our
TarFisDock server, we used it to search for candidate binding
proteins for 4H-tamoxifen in the PDTD. The target candidates
so thus identiﬁed are listed in Supplementary Table S3, and
those which correspond to proteins identiﬁed experimentally
are shown in Table 3. Three amongst the top 2% of the can-
didates are known targets of 4H-tamoxifen, namely dihydro-
folate reductase, immunoglobulin and glutathione transferase.
The top 5% of the candidates include two additional targets
identiﬁed experimentally, i.e. human ﬁbroblast collagenase
and 17b-hydroxysteroid dehydrogenase. Of experimentally
conﬁrmed targets for 4H-tamoxifen 30 and 50% appear
amongst the top 2 and 5% of the TarFisDock predicted
candidates,respectively, indicatingthe reliabilityofthisserver
tool again.
TarFisDock has been in use for about 9 months, and over
1000 small molecules, including synthetic compounds,
existing drugs and natural products, have been screened.
Five groups outside the authors’ labs have become involved
in screening. Experimental evidence has been obtained to
conﬁrm that binding proteins identiﬁed by TarFisDock for
several compounds indeed display binding activity. In one
case, that of a binding protein for a natural product, not
only was binding veriﬁed experimentally, but a complex
was obtained whose 3D crystal structure was solved by
X-ray crystallography (data not shown). The computing
time required depends on the ﬂexibility of the given com-
pound. Thus, TarFisDock may ﬁnish the PDTD search within
5–20 h using one CPU of the SGI Origin3800 superserver.
SUMMARY
In bringing together the target database PDTD and the reverse
docking program, TarFisDock server is a convenient tool for
identiﬁcation of potential binding proteins for small molecules
such as drugs, lead compounds and natural products. Totally,
this web server has already been tested for over 1000 small
molecules, the binding proteins for several molecules have
been veriﬁed by bioassay including crystal structure
determination (data not shown). This web server can also
Figure 2. An example of the input and output of TarFisDock.
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existing drug or a drug candidate. In general, one drug
molecule may interact with several targets including targets
associated with side effect (toxicity). As illustrated by the
examples for identifying potential binding proteins of vitamin
E and 4H-tamxifen, TarFisDock provides multiple options for
selecting protein targets. These are useful clues for further
experimental test in evaluating the efﬁcacy and toxicity of
the drug. On the other hand, the targets information produced
by TarFisDock is also signiﬁcant for functional genomic
study with the chemical biology paradigm (33). In general,
TarFisDock web sever is a convenient tool for ‘ﬁshing’ the
target proteins of small molecules, the user just inputs the
structure of querying compound and customizes a target list
from PDTD (a list of all the targets is recommended).
However, TarFisDock still has certain limitations. The
major one is that the protein entries are not enough for cov-
ering all the protein information of disease related genomes.
The second one is that TarFisDock has not considered the
ﬂexibility of proteins during docking simulation. These two
aspects will produce negative false. Another limitation is that
the scoring function for reverse docking is not accurate
enough, which will produce positive false. To overcome
these shortages, we are (i) collecting proteins structures
(experimental and modeling structures) as more as possible
for enlarging PDTD, (ii) developing new docking program
including protein ﬂexibility, and (iii) establishing accurate
scoring function. TarFisDock and PDTD are available at
http://www.dddc.ac.cn/tarﬁsdock/.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR online.
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